Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 3/2005

01.06.2005 | Original Article

Surgical treatment of hepatocellular carcinoma in China

Surgical techniques, indications, and outcomes

verfasst von: Xiao-Ping Chen, Zhi-Yong Huang

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Surgery remains the most effective treatment for hepatocellular carcinoma (HCC). While resection and liver transplantation achieve the best outcomes in patients with small HCC, controversy surrounds treatment of large HCC, HCC with portal vein tumor thrombus, and HCC with hypersplenism.

Patient/methods

From January 1988 to December 2002, 2,102 patients with large HCC underwent hepatectomy in our hospital. The traditional resection method was used on 959 patients, after which the improved new method was used on 1,143 patients. Meanwhile, from January 1990 until December 2003, hepatic resection ± thrombectomie has been performed in 438 patients with HCC and portal vein tumor thrombus. Among them, 286 patients showed portal vein tumor thrombus located in the primary and secondary branch of the main portal vein (group A), and 152 patients showed portal vein tumor thrombus (PVTT) involved in the main portal vein (group B). Additionally, out of 204 HCC patients with cirrhotic hypersplenism, 94 patients had hepatectomy and splenectomy, and 100 patients had only hepatectomy without hospital death.

Results

The 3- and 5-year survival after resection of large HCCs (over 5 cm) with improved new method in China was between 50.7 and 58.8% and 27.9 and 38.7%, respectively. Tumor recurrence in the liver within 1 year after hepatic resection + thrombectomie was detected in 45% of group A and in 78.8% in group B. The cumulative 5-year overall survival rates were 18.1% for group A and 0% for group B. The 1-, 3-, and 5-year overall survival in HCC plus portal vein tumor thrombus (PVTT) was 58.7, 22.7, and 18.1%. The hepatectomy/splenectomy group had a 5-year tumor-free survival rate of 37.2% and the hepatectomy group alone had 27.2%.

Conclusion

The new resection methods, hepatic resection + thrombectomy and hepatectomy + splenectomy, are very effective treatments for large HCC, HCC with portal vein tumor thrombus, and HCC with hypersplenism, respectively. Local treatment modalities, e.g. percutaneous ethanol injection, cryosurgery, and radiofrequency ablation as well as microwave coagulation are used in patients with poor liver function in small and large HCCs.
Literatur
1.
Zurück zum Zitat Lau WY, Ho S, Leung TWT, Chan M, Ho R, Johnson PJ, Li AK (1998) Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intraarterial infusion of yttrium-90 microspheres. Int J Radiat Oncol Biol Phys 40:583–592CrossRefPubMed Lau WY, Ho S, Leung TWT, Chan M, Ho R, Johnson PJ, Li AK (1998) Selective internal radiation therapy for non-resectable hepatocellular carcinoma with intraarterial infusion of yttrium-90 microspheres. Int J Radiat Oncol Biol Phys 40:583–592CrossRefPubMed
2.
Zurück zum Zitat Chen XP, Qiu FZ (1983) Current status of the surgical management of primary liver cancer in China. Acta Acad Med Wuhan 3:60–64PubMed Chen XP, Qiu FZ (1983) Current status of the surgical management of primary liver cancer in China. Acta Acad Med Wuhan 3:60–64PubMed
3.
Zurück zum Zitat Chen XP, Wu ZD, Qiu FZ (2000) The history, present and prospect of the surgical treatment of primary liver cancer in China. Chin J Bases Clin Gen Surg 7:257–258 Chen XP, Wu ZD, Qiu FZ (2000) The history, present and prospect of the surgical treatment of primary liver cancer in China. Chin J Bases Clin Gen Surg 7:257–258
4.
Zurück zum Zitat Wu MC (2002) Clinical and experimental research of primary liver cancer in China. Chin-German J Clin Oncol 1:1–4 Wu MC (2002) Clinical and experimental research of primary liver cancer in China. Chin-German J Clin Oncol 1:1–4
5.
Zurück zum Zitat Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 39:1434–1440CrossRef Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 39:1434–1440CrossRef
6.
Zurück zum Zitat Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, Kosuge T, Okada S, Takayasu K, Yamasaki S (1998) Early hepatocellular carcinoma as an entity with high rate of surgical cure. Hepatology 28:1241–1246CrossRefPubMed Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, Kosuge T, Okada S, Takayasu K, Yamasaki S (1998) Early hepatocellular carcinoma as an entity with high rate of surgical cure. Hepatology 28:1241–1246CrossRefPubMed
7.
Zurück zum Zitat Fong Y, Sun RL, Jarnagin W, Blumgart LH (1999) An analysis of 412 cases of hepatocellular carcinoma at a western center. Ann Surg 229:790–799CrossRefPubMed Fong Y, Sun RL, Jarnagin W, Blumgart LH (1999) An analysis of 412 cases of hepatocellular carcinoma at a western center. Ann Surg 229:790–799CrossRefPubMed
8.
Zurück zum Zitat Yao FY, Ferrell L, Bass NM, Watson JJ, Baccetti P, Venook A, Ascher NL, Roberts JP (2001) Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival. Hepatology 33:1394–1403CrossRefPubMed Yao FY, Ferrell L, Bass NM, Watson JJ, Baccetti P, Venook A, Ascher NL, Roberts JP (2001) Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival. Hepatology 33:1394–1403CrossRefPubMed
9.
Zurück zum Zitat Chen XP, Qiu FZ, Wu ZD, Zhang BX (2004) Chinese experience with hepatotectomy for huge hepatocellular carcinoma. Br J Surg 91:322–326CrossRefPubMed Chen XP, Qiu FZ, Wu ZD, Zhang BX (2004) Chinese experience with hepatotectomy for huge hepatocellular carcinoma. Br J Surg 91:322–326CrossRefPubMed
10.
Zurück zum Zitat Chen XP, Wu ZD, Qiu FZ (1984) An experimental study of the longest tolerable time of the total portal tried occlusion in normothermia in rabbits. Chin J Surg 3:153–155 Chen XP, Wu ZD, Qiu FZ (1984) An experimental study of the longest tolerable time of the total portal tried occlusion in normothermia in rabbits. Chin J Surg 3:153–155
11.
Zurück zum Zitat Chen XP, Wu ZD, Qiu FZ (1989) Clinical observation of long time of the total portal tried occlusion in normothermia in 81 cases. Chin J Surg 9:523–524 Chen XP, Wu ZD, Qiu FZ (1989) Clinical observation of long time of the total portal tried occlusion in normothermia in 81 cases. Chin J Surg 9:523–524
12.
Zurück zum Zitat Launois B (2000) The intrahepatic glissonian approach to liver resection. In: Blumgart LH, Fong Y (eds) Surgery of the Liver and Biliary Tract. Saunders, London, pp 1698–1703 Launois B (2000) The intrahepatic glissonian approach to liver resection. In: Blumgart LH, Fong Y (eds) Surgery of the Liver and Biliary Tract. Saunders, London, pp 1698–1703
13.
Zurück zum Zitat Chen XP, Wu ZD, Qiu FZ (1999) Right hemihepatectomy of directly tie off afferent and efferent hepatic vessels of the tumor-bearing liver. Chin J Pract Surg 19:678–679 Chen XP, Wu ZD, Qiu FZ (1999) Right hemihepatectomy of directly tie off afferent and efferent hepatic vessels of the tumor-bearing liver. Chin J Pract Surg 19:678–679
14.
Zurück zum Zitat Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M (2002) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer 95:588–595CrossRefPubMed Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M (2002) Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer 95:588–595CrossRefPubMed
15.
Zurück zum Zitat Llovet JM, Bustamante J, Castells A, Vilana R, Aguso Mdel C, Sala M, Bru C, Rodes J, Bruix J (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29:62–67CrossRefPubMed Llovet JM, Bustamante J, Castells A, Vilana R, Aguso Mdel C, Sala M, Bru C, Rodes J, Bruix J (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29:62–67CrossRefPubMed
16.
Zurück zum Zitat Yamada K, Izaki K, Sugimoto K, Magahara H, Morita Y, Yoden E, Matsumoto S, Soejima T, Sugimura K (2003) Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 57:113–119CrossRefPubMed Yamada K, Izaki K, Sugimoto K, Magahara H, Morita Y, Yoden E, Matsumoto S, Soejima T, Sugimura K (2003) Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 57:113–119CrossRefPubMed
17.
Zurück zum Zitat Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397–401PubMed Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397–401PubMed
18.
Zurück zum Zitat Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY (1997) The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal obstruction. A prospective controlled study. Cancer 79:2087–2093CrossRefPubMed Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY (1997) The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal obstruction. A prospective controlled study. Cancer 79:2087–2093CrossRefPubMed
19.
Zurück zum Zitat Livraghi T, Grigioni W, Mazziotti A, Sangalli G, Vettori C (1990) Percutaneous ethanol injection of portal thrombosis in hepatocellular carcinoma: a new possible treatment. Tumor 76:394–397 Livraghi T, Grigioni W, Mazziotti A, Sangalli G, Vettori C (1990) Percutaneous ethanol injection of portal thrombosis in hepatocellular carcinoma: a new possible treatment. Tumor 76:394–397
20.
Zurück zum Zitat Sitzmann JV, Abrams R (1993) Improved survival for hepatocellular carcinoma with combination surgery and multimodality treatment. Ann Surg 217:149–154PubMed Sitzmann JV, Abrams R (1993) Improved survival for hepatocellular carcinoma with combination surgery and multimodality treatment. Ann Surg 217:149–154PubMed
21.
Zurück zum Zitat Yamanaka N, Okamoto E, Fujihara S, Kato T, Fujimoto J, Oriyama T, Mitsunobu M, Toyosaka A, Uematsu K, Yamamoto K (1992) Do the tumor cells of hepatocellular carcinoma dislodge into the portal venous system during hepatic resection? Cancer 70:2263–2267PubMed Yamanaka N, Okamoto E, Fujihara S, Kato T, Fujimoto J, Oriyama T, Mitsunobu M, Toyosaka A, Uematsu K, Yamamoto K (1992) Do the tumor cells of hepatocellular carcinoma dislodge into the portal venous system during hepatic resection? Cancer 70:2263–2267PubMed
22.
Zurück zum Zitat Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, Fujimoto J, Oriyama T, Furukawa K, Kawamura E (1990) Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 65:1104–1110PubMed Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, Fujimoto J, Oriyama T, Furukawa K, Kawamura E (1990) Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 65:1104–1110PubMed
23.
Zurück zum Zitat Shimada M, Takenaka K, Kawahara N, Kajiyama K, Yamamoto K, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K (1996) Surgical treatment strategy for patients with stage hepatocellular carcinoma. Surgery 119:517–522PubMed Shimada M, Takenaka K, Kawahara N, Kajiyama K, Yamamoto K, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K (1996) Surgical treatment strategy for patients with stage hepatocellular carcinoma. Surgery 119:517–522PubMed
24.
Zurück zum Zitat Fuster J, Garcia-Valdecasas JC, Grande L, Tabet J, Bruix J, Anglada T, Taura P, Lacy AM, Gonzalez X, Vilana R, Bru C, Sole M, Visa J (1996) Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg 223:297–302CrossRefPubMed Fuster J, Garcia-Valdecasas JC, Grande L, Tabet J, Bruix J, Anglada T, Taura P, Lacy AM, Gonzalez X, Vilana R, Bru C, Sole M, Visa J (1996) Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg 223:297–302CrossRefPubMed
25.
Zurück zum Zitat Fong Y, Sun RL, Jarnagin W, Blumgart LH (1999) An analysis of 412 casses of hepatocellular carcinoma at a western center. Ann Surg 229:790–800CrossRefPubMed Fong Y, Sun RL, Jarnagin W, Blumgart LH (1999) An analysis of 412 casses of hepatocellular carcinoma at a western center. Ann Surg 229:790–800CrossRefPubMed
26.
Zurück zum Zitat Ikai I, Yamaoka Y, Yamamoto Y, Ozaki N, Sakai Y, Satoh S, Shinkura N, Yamamoto M (1998) Surgical intervention for patients with stage—a hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg 227:433–439CrossRefPubMed Ikai I, Yamaoka Y, Yamamoto Y, Ozaki N, Sakai Y, Satoh S, Shinkura N, Yamamoto M (1998) Surgical intervention for patients with stage—a hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg 227:433–439CrossRefPubMed
27.
Zurück zum Zitat Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I (1994) Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 106:720–727PubMed Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I (1994) Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 106:720–727PubMed
28.
Zurück zum Zitat Fujii T, Takayasu K, Muramatsu Y, Moriyama N, Wakao F, Kosuge T, Takayama T, Makuuchi M, Yamasaki S, Okazaki N (1993) Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 23:105–109PubMed Fujii T, Takayasu K, Muramatsu Y, Moriyama N, Wakao F, Kosuge T, Takayama T, Makuuchi M, Yamasaki S, Okazaki N (1993) Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 23:105–109PubMed
29.
Zurück zum Zitat Hirai K, Kawazoe Y, Yamashita K, Kumagai M, Tanaka M, Sakai T, Inoue R, Eguchi S, Majima Y, Abe M (1986) Transcatheter partial splenic arterial embolization in patients with hypersplenism: a clinical evaluation as supporting therapy for hepatocellular carcinoma and liver cirrhosis. Hepatogastroenterology 33:105–108PubMed Hirai K, Kawazoe Y, Yamashita K, Kumagai M, Tanaka M, Sakai T, Inoue R, Eguchi S, Majima Y, Abe M (1986) Transcatheter partial splenic arterial embolization in patients with hypersplenism: a clinical evaluation as supporting therapy for hepatocellular carcinoma and liver cirrhosis. Hepatogastroenterology 33:105–108PubMed
30.
Zurück zum Zitat Lokich J, Costello P (1983) Splenic embolization to prevent dose limitation of cancer chemotherapy. Am J Roentgenol 140:159–161 Lokich J, Costello P (1983) Splenic embolization to prevent dose limitation of cancer chemotherapy. Am J Roentgenol 140:159–161
31.
Zurück zum Zitat Yoshimi F, Meigata K, Nagao T, Fukushima S, Uchida H, Wakabayashi T (1994) Hepatocellular carcinoma with a solitary adrenal metastasis and poor hepatic functional reserve: report of a case. Surg Today 24:268–271PubMed Yoshimi F, Meigata K, Nagao T, Fukushima S, Uchida H, Wakabayashi T (1994) Hepatocellular carcinoma with a solitary adrenal metastasis and poor hepatic functional reserve: report of a case. Surg Today 24:268–271PubMed
32.
Zurück zum Zitat Shimada M, Hashizume M, Shirabe K, Takenaka K, Sugimachi K (2000) A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism: performing a hepatectomy after a laparoscopic splenectomy. Surg Endosc 14:127–130PubMed Shimada M, Hashizume M, Shirabe K, Takenaka K, Sugimachi K (2000) A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism: performing a hepatectomy after a laparoscopic splenectomy. Surg Endosc 14:127–130PubMed
33.
Zurück zum Zitat Yoshimi F, Meigata K, Nagao T, Fukushima S, Uchida H, Wakabayashi T (1994) Hepatocellular carcinoma with a solitary adrenal metastasis and poor hepatic functional reserve: report of a case. Surg Today 24:268–271PubMed Yoshimi F, Meigata K, Nagao T, Fukushima S, Uchida H, Wakabayashi T (1994) Hepatocellular carcinoma with a solitary adrenal metastasis and poor hepatic functional reserve: report of a case. Surg Today 24:268–271PubMed
34.
Zurück zum Zitat Sugawara Y, Yamamoto J, Shimada K, Yamasaki S, Kosuge T, Takayama T, Makuuchi M (2000) Splenectomy in patients with hepatocellular carcinoma and hypersplenism. J Am Coll Surg 190:446–450CrossRefPubMed Sugawara Y, Yamamoto J, Shimada K, Yamasaki S, Kosuge T, Takayama T, Makuuchi M (2000) Splenectomy in patients with hepatocellular carcinoma and hypersplenism. J Am Coll Surg 190:446–450CrossRefPubMed
35.
Zurück zum Zitat Aoe T, Okamoto Y, Saito T (1995) Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181:1881–1886CrossRefPubMed Aoe T, Okamoto Y, Saito T (1995) Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181:1881–1886CrossRefPubMed
36.
Zurück zum Zitat Ringe B, Pichlmayr R, Wittekind C, Tusch G (1991) Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 15:270–285PubMed Ringe B, Pichlmayr R, Wittekind C, Tusch G (1991) Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 15:270–285PubMed
37.
Zurück zum Zitat Iwatsuki S, Gordon RD, Shaw BW Jr, Starzl TE (1985) Role of liver transplantation in cancer therapy. Ann Surg 202:401–407PubMed Iwatsuki S, Gordon RD, Shaw BW Jr, Starzl TE (1985) Role of liver transplantation in cancer therapy. Ann Surg 202:401–407PubMed
38.
Zurück zum Zitat O’Grady JG, Polson RJ, Rolles K, Calne RY, Williams R (1988) Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 207:373–379PubMed O’Grady JG, Polson RJ, Rolles K, Calne RY, Williams R (1988) Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg 207:373–379PubMed
39.
Zurück zum Zitat Ismail T, Angrisani L, Gunson BK, Hubscher G, Buckels JAC, Neuberger JM, Elias E, McMaster P (1990) Primary hepatic malignancy. The role of liver transplantation. Br J Surg 77:983–987PubMed Ismail T, Angrisani L, Gunson BK, Hubscher G, Buckels JAC, Neuberger JM, Elias E, McMaster P (1990) Primary hepatic malignancy. The role of liver transplantation. Br J Surg 77:983–987PubMed
40.
Zurück zum Zitat Pichlmayr R, Weimann A, Ringe B (1994) Indications for liver transplantation in hepatobiliary malignancy. Hepatology 20:33S–40SCrossRefPubMed Pichlmayr R, Weimann A, Ringe B (1994) Indications for liver transplantation in hepatobiliary malignancy. Hepatology 20:33S–40SCrossRefPubMed
41.
Zurück zum Zitat Bismuth H, Chiche L, Castaing D (1995) Surgical treatment of hepatocellular carcinomas in non-cirrhotic liver: experience with 68 liver resections. World J Surg 19:35–41CrossRefPubMed Bismuth H, Chiche L, Castaing D (1995) Surgical treatment of hepatocellular carcinomas in non-cirrhotic liver: experience with 68 liver resections. World J Surg 19:35–41CrossRefPubMed
42.
Zurück zum Zitat Schwartz M, Sung M, Mor E, Fisher A, Popescu I, Fiel I, Sheiner P, Emre S, Guy S, Miller CM (1995) A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J Am Coll Surg 180:596–603PubMed Schwartz M, Sung M, Mor E, Fisher A, Popescu I, Fiel I, Sheiner P, Emre S, Guy S, Miller CM (1995) A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J Am Coll Surg 180:596–603PubMed
43.
Zurück zum Zitat Mazzafero V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabtto A, Gennari L (1996) liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 334:693–699CrossRefPubMed Mazzafero V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabtto A, Gennari L (1996) liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 334:693–699CrossRefPubMed
44.
Zurück zum Zitat Mcpeake JR, O’Grady JG, Zaman S, Portmann B, Wight DGD, Tan KC, Calne RY, Williams R (1993) liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol 18:226–234CrossRefPubMed Mcpeake JR, O’Grady JG, Zaman S, Portmann B, Wight DGD, Tan KC, Calne RY, Williams R (1993) liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol 18:226–234CrossRefPubMed
45.
Zurück zum Zitat Dmitrewski J, El-Gazzaz G, McMaster P (1998) Hepatocellular cancer: resection or transplantation. J Hepatol Bil Pancr Surg 5:18–23 Dmitrewski J, El-Gazzaz G, McMaster P (1998) Hepatocellular cancer: resection or transplantation. J Hepatol Bil Pancr Surg 5:18–23
46.
Zurück zum Zitat Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, Vilane R, Rodes J (1993) Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 18:1121–1126CrossRefPubMed Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, Vilane R, Rodes J (1993) Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 18:1121–1126CrossRefPubMed
47.
Zurück zum Zitat Ohnishi K (1998) Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatogastroenterology 45:1254–1258PubMed Ohnishi K (1998) Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatogastroenterology 45:1254–1258PubMed
48.
Zurück zum Zitat Adam R, Akpinar E, Johann M, Kunstlinger F, Majno P, Bismuth H (1997) Place of cryosurgery in the treatment of malignant liver tumors. Ann Surg 225:39–50CrossRefPubMed Adam R, Akpinar E, Johann M, Kunstlinger F, Majno P, Bismuth H (1997) Place of cryosurgery in the treatment of malignant liver tumors. Ann Surg 225:39–50CrossRefPubMed
49.
50.
Zurück zum Zitat Pearson AS, Izzo F, Fleming D, Ellis LM, Delrio P, Roh MS, Granchi J, Curley SA (1999) Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 178:592–599CrossRefPubMed Pearson AS, Izzo F, Fleming D, Ellis LM, Delrio P, Roh MS, Granchi J, Curley SA (1999) Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 178:592–599CrossRefPubMed
51.
Zurück zum Zitat Buscarini L, Rossi S (1997) Technology for radiofrequency thermal ablation of liver tumors. Semin Laparosc Surg 4:96–101PubMed Buscarini L, Rossi S (1997) Technology for radiofrequency thermal ablation of liver tumors. Semin Laparosc Surg 4:96–101PubMed
52.
Zurück zum Zitat Murakami R, Yoshimatsu S, Yamashita Y, Matsukawa T, Takahashi M, Sagara K (1995) Treatment of hepatocellular carcinoma: value of percutaneous microwave coagulation. AJR Am J Roentgenol 164:1159–1164 Murakami R, Yoshimatsu S, Yamashita Y, Matsukawa T, Takahashi M, Sagara K (1995) Treatment of hepatocellular carcinoma: value of percutaneous microwave coagulation. AJR Am J Roentgenol 164:1159–1164
53.
Zurück zum Zitat Song SB, Zhang TL, Xiu DR, Yuan J, Wang DC, Jiang B, Wang CM (2004) Effective evaluation of liver transplantation for hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 84:1533–1535PubMed Song SB, Zhang TL, Xiu DR, Yuan J, Wang DC, Jiang B, Wang CM (2004) Effective evaluation of liver transplantation for hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 84:1533–1535PubMed
54.
Zurück zum Zitat Xu X, Zheng SS, Liang TB, Wang WL, Jin J, Shen Y, Wu J, Yu J (2004) Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi. Hepatobiliary Pancreat Dis Int 3:341–344PubMed Xu X, Zheng SS, Liang TB, Wang WL, Jin J, Shen Y, Wu J, Yu J (2004) Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi. Hepatobiliary Pancreat Dis Int 3:341–344PubMed
55.
Zurück zum Zitat Zhao JC, Lu SC, Yan LN, Li B, Wen TF, Zeng Y, Cheng NS, Wang J, Luo Y, Pen YL (2003) Incidence and treatment of hepatic artery complications after orthotopic liver transplantation. World J Gastroenterol 9:2853–2855PubMed Zhao JC, Lu SC, Yan LN, Li B, Wen TF, Zeng Y, Cheng NS, Wang J, Luo Y, Pen YL (2003) Incidence and treatment of hepatic artery complications after orthotopic liver transplantation. World J Gastroenterol 9:2853–2855PubMed
56.
Zurück zum Zitat Chen ZS, Zeng FJ, Ming CS, Lin ZB, Zhang WJ, Wei L, Zhu XH, Jiang JP, Chen ZK (2004) The survival and value of liver transplantation for liver carcinoma: a single-center experience. Transplant Proc 36:2284–2286CrossRefPubMed Chen ZS, Zeng FJ, Ming CS, Lin ZB, Zhang WJ, Wei L, Zhu XH, Jiang JP, Chen ZK (2004) The survival and value of liver transplantation for liver carcinoma: a single-center experience. Transplant Proc 36:2284–2286CrossRefPubMed
57.
Zurück zum Zitat Lencioni R, Cioni D, Crocetti L, Bartolozzi C (2004) Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl 10:S91–S97CrossRefPubMed Lencioni R, Cioni D, Crocetti L, Bartolozzi C (2004) Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl 10:S91–S97CrossRefPubMed
58.
Zurück zum Zitat Wong WS, Patel SC, Cruz FS, Gala KV, Turner AF (1998) Cryosurgery as a treatment for advanced stage hepatocellular carcinoma: results, complications, and alcohol ablation. Cancer 82:1268–1278CrossRefPubMed Wong WS, Patel SC, Cruz FS, Gala KV, Turner AF (1998) Cryosurgery as a treatment for advanced stage hepatocellular carcinoma: results, complications, and alcohol ablation. Cancer 82:1268–1278CrossRefPubMed
59.
Zurück zum Zitat Zhou X, Tang Z, Yu Y (1996) Long-term results of multimodality treatment in patients with primary liver cancer. Zhonghua Wai Ke Za Zhi 34:518–521PubMed Zhou X, Tang Z, Yu Y (1996) Long-term results of multimodality treatment in patients with primary liver cancer. Zhonghua Wai Ke Za Zhi 34:518–521PubMed
60.
Zurück zum Zitat Yin XY, Xie XY, Lu MD, Chen JW, Xu HX, Xu ZF, Liu GJ, Huang B (2004) Ultrasound-guided percutaneous composite thermal ablation technique in treatment of medium and large hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 42:1029–1032PubMed Yin XY, Xie XY, Lu MD, Chen JW, Xu HX, Xu ZF, Liu GJ, Huang B (2004) Ultrasound-guided percutaneous composite thermal ablation technique in treatment of medium and large hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 42:1029–1032PubMed
Metadaten
Titel
Surgical treatment of hepatocellular carcinoma in China
Surgical techniques, indications, and outcomes
verfasst von
Xiao-Ping Chen
Zhi-Yong Huang
Publikationsdatum
01.06.2005
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 3/2005
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-005-0552-9

Weitere Artikel der Ausgabe 3/2005

Langenbeck's Archives of Surgery 3/2005 Zur Ausgabe

Current Concepts in Clinical Surgery

Diagnostic laparoscopy: indications and benefits

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.